CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Chemomab Therapeutics Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.17−0.09 (-7.51%)
Close on Oct 19, 2026
- Market cap
- $749.09M
- P/E (TTM)
- 65.0
- Dividend yield
- –
Chemomab Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.41M | $166.30M |
| Enterprise Value | $1.71M | $88.19M |
| PE Ratio | 0.81 | 20.44 |
| PB Ratio | 0.97 | 2.03 |
| P/TBV Ratio | 0.97 | 2.29 |
Income (trailing twelve months)
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$112.00M | -$21.40M |
| Pretax Income | -$9.00M | -$14.34M |
| Net Income | -$9.00M | -$22.46M |
| EBITDA | -$112.00M | -$16.91M |
| EPS (Diluted) | $0.02 | -$0.83 |
Returns
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -97.9% | -53.2% |
| Return on Assets (ROA) | -84.2% | -40.9% |
| Return on Invested Capital (ROIC) | -8102.6% | -32.4% |
| Return on Capital Employed (ROCE) | -1289.6% | -38.1% |
Growth
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| EPS Growth (YoY) | -53.8% | -26.2% |
| EPS Growth (3Y CAGR) | -47.0% | -0.17% |
| EPS Growth (5Y CAGR) | -16.4% | 3.77% |
Balance sheet
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $6.70M | $61.43M |
| Net Cash (Debt) | $6.70M | $15.35M |
| Net Cash Per Share | $0.01 | $0.66 |
| Equity (Book Value) | $8.69M | $49.09M |
| Book Value Per Share | $0.02 | $1.37 |
| Tangible Book Value | $8.69M | $23.52M |
| Working Capital | $8.40M | $76.81M |
Financial position
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.41 | 3.34 |
| Quick Ratio | 4.31 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.13M | -$12.35M |
| Capital Expenditures | -$3.00K | -$1.08M |
| Free Cash Flow | -$11.13M | -$20.22M |
| FCF Per Share | -$0.02 | -$0.42 |
Efficiency
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$899.50K | -$703.34K |
| Employee Count | 10 | 74 |
Dividends and yields
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -106.9% | -23.3% |
| FCF Yield | -132.3% | -8.72% |
Shares
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 575,381,000 | 58,127,000 |
| Shares Change (YoY) | 42.1% | 10.9% |
| Float | 492,486,000 | 49,136,700 |
| Shares Held by Insiders | 14.4% | 11.6% |
| Shares Held by Institutions | 0.07% | 59.4% |
Taxes
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Chemomab Therapeutics | Industry median |
|---|---|---|
| Graham Number | $0.08 | $18.73 |
| Graham Upside | 434.6% | -45.1% |
| Altman Z-Score | -47.67 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Chemomab Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.